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Abstract
Comprehensive analyses of cancer genomes promise to inform prognoses and precise cancer
treatments. A major barrier, however, is inaccessibility of metastatic tissue. A potential solution is
to characterize circulating tumor cells (CTCs), but this requires overcoming the challenges of
isolating rare cells and sequencing low-input material. Here we report an integrated process to
isolate, qualify and sequence whole exomes of CTCs with high fidelity, using a census-based
sequencing strategy. Power calculations suggest that mapping of >99.995% of the standard exome
is possible in CTCs. We validated our process in two prostate cancer patients including one for
whom we sequenced CTCs, a lymph node metastasis and nine cores of the primary tumor. Fifty-
one of 73 CTC mutations (70%) were observed in matched tissue. Moreover, we identified 10
early-trunk and 56 metastatic-trunk mutations in the non-CTC tumor samples and found 90% and
73% of these, respectively, in CTC exomes. This study establishes a foundation for CTC genomics
in the clinic.
Enabling precision medicine for each cancer patient depends on the ability to access samples
that accurately represent the genomic features of their tumor1. Two critical bottlenecks,
however, are that metastatic tissue is often inaccessible and the purity and yield of biopsy
samples are low. To date, genomic characterization of cancer has emphasized large-scale
sequencing of primary tumors and in few cases, metastatic lesions2. Both circulating tumor
DNA (ctDNA)3 and circulating tumor cells (CTCs)4 represent alternative sources that may
overcome these sampling challenges. Comprehensive sequencing and confident
determination of genomic variants in CTCs could provide routine monitoring of transiting
cells with potential for metastatic colonization to complement the static sampling of resected
or biopsied lesions5.
Technologies for enriching and enumerating CTCs have provided prognostic value4,6,7, and
characterizing specific regions, genes or patterns of gene expression in CTCs is both
possible and useful. PCR-based methods, array CGH and high-throughput sequencing have
revealed somatic single nucleotide variants (SSNVs) and copy number alterations8–10, and
RNA sequencing has shown pathways implicated in metastasis11. For example, exome
sequencing of lung cancer CTCs can uncover mutations shared with metastases10. However,
without comprehensive power statistics, it remains difficult to assess the fraction of CTC
exomes that are being robustly and accurately sequenced and whether such approaches
apply to other cancers like prostate cancer.
Robust and accurate detection of SSNVs from CTCs is challenging. CTCs in a vial of blood
are sparse12, and whole genome amplification (WGA) is necessary to construct sequencing
libraries. Yields of amplified DNA vary among CTCs13, and WGA introduces amplification
bias and polymerase errors14,15. “Census-based sequencing” of multiple libraries from the
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distinguish private mutations from polymerase errors with some fidelity14,15. Despite
technical capabilities demonstrated for sequencing CTCs, no generalizable framework exists
for confidently calling SSNVs, and design optimization of the experimental processes could
provide a critical foundation for future comprehensive surveys of the genomics of CTCs
across large numbers of samples.
Based on these considerations, we developed a modular set of experimental and analytical
protocols for census-based whole exome sequencing (WES) and confident calling of SSNVs
from prostate CTCs. We show these techniques can provide a window into the genetics of
metastatic prostate cancer in a manner that is potentially useful clinically.
We first created a standardized process to generate and qualify multiple independent
libraries for WES from CTCs recovered from one vial of blood. The process involves cell
enrichment and isolation, genomic amplification, library qualification and census-based
sequencing (Fig. 1a, Supplementary Fig. 1). We used the Illumina MagSweeper to enrich
EpCAM-expressing CTCs16. The recovered cells, enriched with CTCs, were deposited into
dense arrays of subnanoliter wells and imaged by automated epifluorescence imaging (Fig.
1b). Individual EpCAM (+) CD45 (−) CTCs were recovered by robotic micromanipulation
for WGA using multiple displacement amplification (MDA). In all, this combined process
reliably isolated single CTCs in a highly automated fashion (Supplementary Fig. 2).
We next validated our method for isolating CTCs. The yield of tumor cells spiked into
whole blood was ≥85% (Supplementary Fig. 3) and concurred with an independent method
for enrichment (Veridex CellSearch) (Supplementary Fig. 4). We also performed low-
coverage single-cell RNA-sequencing on cells recovered through our process from prostate
cancer patients to confirm our isolated EpCAM (+) cells expressed prostate-specific antigen
(PSA), confirming their prostate origins (Supplementary Fig. 5). We then enriched and
enumerated CTCs from 51 blood samples of 36 patients with metastatic castration-resistant
prostate cancer (CRPC) (Supplementary Table 1). The automated process was used for 45 of
the 51 samples, and manual picking was performed for the remaining 6 samples. These
samples yielded 0 to 200 CTCs per 3.75 mL of blood (median of 7 for samples with ≥1
CTCs, with 27% having no detectable CTCs); 45% of samples had ≥5, consistent with
volume-adjusted counts previously reported in metastatic prostate cancer12. The number of
CTCs also correlated with serum levels of PSA (p = 0.004; Spearman, two-tailed) (Fig. 1c).
We reasoned that establishing methods to assess the quality and uniformity of genome-wide
coverage of CTC-derived sequencing libraries prior to in-depth WES or whole-genome
sequencing (WGS) would help make census-based genomic sequencing of CTCs cost-
efficient and facilitate subsequent analysis of SSNVs. To address this challenge, we first
performed WGA on all single CTCs isolated from five patients with 20 or more CTCs and
in which matched tumor tissue was available in tumor banks for comparison. As expected,
the rates of success in amplification of single prostate CTCs varied widely (11–100%)
(Supplementary Fig. 1), consistent with variability reported for amplifying lung cancer
CTCs13. To assess the level of amplification bias in the recovered products, we developed a
rapid and cost-effective method using low-pass WGS (< 0.05×) and autocorrelation analysis
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tof single-base coverage to qualify libraries prior to WES (Online Methods). This metric
accurately predicted the fraction of well-covered targets in subsequent WES (p < 0.0001;
Pearson, two-tailed) (Fig. 1d). It also corresponded well to low-resolution views (1 Mb) of
genome-wide read densities, highlighting prominent hallmarks of copy-number variants in
prostate cancer, including chromosome 8q amplification, 8p deletion and amplification of
chromosome X (Fig. 1e)17. When a library generated insufficient coverage (~ 0.0001×) to
calculate an autocorrelation coefficient accurately, visual inspection of genome-wide read
density could provide a qualitative means for qualification (Supplementary Fig. 6).
Together, these examples demonstrate that our integrated experimental approach generates
independent, high-quality libraries from single CTCs for WES and that low pass WGS can
reliably predict which single CTC sequencing libraries are likely to yield high-quality data.
We then implemented a sensitive method to detect SSNVs from CTC libraries. We selected
WES to generate high-coverage sequencing data of maximally informative genomic regions
to enable cost-effective discovery of SSNVs. We sequenced 19 single CTC libraries of
patient CRPC_36 to 124 ± 12× mean target coverage (Supplementary Table 2). As expected,
individual libraries exhibited non-uniform coverage with only a fraction of the exome
present (Supplementary Fig. 7a)15, and bimodal allelic distortion at sites of germline
heterozygous SNPs, compared to normal distributions from bulk sequencing
(Supplementary Fig. 7b). This effect caused improper genotyping at 38.3 ± 9.8% of such
covered sites (Supplementary Fig. 8a). Coverage of either the alternate or both alleles ranged
from 33.5 to 79.6% for individual CTCs and strongly correlated with the autocorrelation
metric used for quality control (p < 0.0001; Spearman, two-tailed) (Fig. 2a).
We hypothesized that combining data from independent CTC libraries would improve
sensitivity. Indeed, the total coverage of both alleles (99.995%) at 22,054 SNP sites among
19 independent CTC libraries compared well to a representative bulk library from the
primary tumor—only 0.005% of sites were improperly genotyped (Fig. 2a, Supplementary
Fig. 8a). Analysis of whole exomes of CTCs from a second patient (CRPC_10) revealed
similar extents of amplification bias that were also overcome by sequencing multiple
independent libraries (Supplementary Fig. 7c,d, 8b,c). (We found that amplifying a single
pool of CTCs was sensitive to the same allelic distortion as any other individual MDA-
derived library (Supplementary Fig. 9a).) Together, these observations are consistent with
stochastic loss of DNA from single cells, random preferential amplification of alleles and
the lack of systematic coverage biases in MDA products14; they also confirm that
sequencing multiple independent libraries of CTCs for a patient can enable robust, highly
sensitive determination of variants.
We next sought to assess the specificity of this approach. We estimated an upper bound for
the rate of false positives by assuming all variants, identified using MuTect18, not present in
bulk tumor samples from the same patient were false positives (Online Methods). This
assumption is conservative because contemporary CTCs may have diverged biologically
from previously resected samples. Although amplifying and sequencing a pool of CTCs
exhibited a false positive rate (~10/Mb) less than that for a single CTC library (~25/Mb),
this rate was still insufficient for accurate calling of mutations on its own (Supplementary
Fig. 9b). When combining multiple single CTC libraries, however, the false positive rate of
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tcalled SSNVs dropped substantially from ~500 per Mb (N = 1 library) to a rate below the
expected mutational rate in treated prostate cancer (~2 per Mb) when observed across two or
more CTCs (Fig. 2b)14,15,19. When increasing the number of multiple observations required
(Supplementary Fig. 10), the false positive rate further diminished to 0.9 per Mb (N = 3)
with an estimated sensitivity of 82.6% (Fig. 2b, Inset). Analysis of six CTCs from CRPC_10
supported our statistical predictions from CRPC_36 that census-based sequencing also
improves specificity (Supplementary Fig. 11a).
Applying this analytical method to the 19 CTCs from CRPC_36, we detected 73 SSNVs (N
= 3; Supplementary Table 3). We found that 51 of these SSNVs (70%) were also present
among nine cores from matched primary tumor and a lymph node metastasis, confirming
that these EpCAM (+) cells were genetically related to the primary prostate cancer in this
patient (Fig. 2c). Similarly applying this analytical method to the six CTCs from CRPC_10
sequenced to 89 ± 8 mean target coverage (Supplementary Table 2), 12 of 22 CTC SSNVs
called (55%) (Supplementary Table 4) were also present among 12 cores from the primary
tumor (Supplementary Fig. 11b). Overall, the sensitivity of this technique increases with the
number of CTC libraries included in the analysis, and reached a relative sensitivity of 88%
using 10 of 19 libraries from CRPC_36 (Fig. 2d).
The results above suggest that comprehensive sequencing of prostate CTCs and accurate
assessments of SSNVs are possible with our approach. We then hypothesized that CTC
sequencing could have clinical utility, perhaps providing a reasonable proxy for metastatic
sampling in disseminated cancer. Clinical sequencing in metastatic prostate cancer is
challenging because metastatic tissue is not routinely sampled20 and computed topographic
(CT)–guided biopsy has a poor success rate with low purity of biopsied lesions21. For
patient CRPC_36, there was widespread metastatic disease (Fig. 3a). Although the vast
majority of the metastases (>10) were not available for sequencing, one neck lymph node
had been resected six months prior to CTC collection. Of the 93 SSNVs detected in this
metastasis, 47 (51%) were detected in CTCs (Fig. 3b). Owing to the timing of the sample
acquisition, the CTCs sequenced could not have derived from this particular metastasis, so
non-overlapping mutations could reflect divergent evolution at different sites, as previously
demonstrated in prostate cancer22,23.
We next asked whether sequencing CTCs could uncover mutations present early in tumor
evolution (trunk mutations) or in the inferred metastatic precursor (metastatic trunk
mutations)24. Such founder mutations in other cancer types (e.g. BRAF in malignant
melanoma or KIT in GIST) represent excellent therapeutic targets25,26. Detecting such
mutations in metastatic patients from other tumor types via simple blood draws might
therefore have considerable clinical utility.
We compared the landscape of mutations in CTCs and the metastatic sample to multiple
samples from the patient’s primary prostate tumor resected 5.3 years earlier. Because
prostate cancer is often histologically multifocal27, we sequenced nine spatially distinct foci
of the primary tumor in regions of uniform Gleason grade (Gleason 4 or 5) with one
exception noted (Fig. 3c). To assess relationships between these foci, the CTCs and the
metastasis sample, we performed hierarchical clustering, excluding sites consistently
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tunderpowered in more than half of the samples (owing to lack of coverage) (Fig. 3c).
Indeed, the primary tumor foci exhibited marked heterogeneity, but as expected, ones from
similar physical regions of the tumor were more closely related to each other than those
from other locations (Fig. 3c,d). Notably, we also identified one particular focus that most
closely resembled the CTCs and the metastasis, suggesting that this focus may share a more
recent common ancestor with the CTCs than other foci. Alhough this focus was Gleason 5,
the score itself did not predict the likely metastatic precursor since other Gleason 5 regions
were not in this evolutionary branch.
We found ten SSNVs, including a mutation in TP53, ubiquitous among all primary foci and
metastasis, suggesting the cancer arose from a single ancestor with divergent evolution
thereafter (Fig. 3d). The CTCs had nine of ten (90%) of these early trunk mutations (Fig.
3e). Notably, despite allelic distortion, these were present in a greater fraction of CTCs
(corrected for power) than the non-trunk mutations on average (p = 0.012; Wilcoxon rank
sum test). Fifty-six mutations were present in both the metastasis and primary tumor (any
foci), and the CTCs had 41 (73%) of these metastatic trunk mutations (Fig. 3e). For patient
CRPC_10, we found the CTCs had all three early trunk mutations for which they were
powered (out of nine) (Supplementary Fig. 11c). Together, these proof-of-concept data
support the notion that CTC sequencing can reveal early mutations in tumor evolution and
those that could be shared among metastatic sites. As such trunk mutations are likely to be
present in the majority of sites in advanced cancer patients, these results suggest clinical
utility for systematic CTC genomics.
Here we have demonstrated the feasibility of sequencing whole exomes of prostate CTCs
and confidently calling SSNVs to provide a minimally invasive window into the mutational
landscape of metastatic prostate cancer. We implemented a systematic process to obtain,
qualify and sequence whole exomes of CTCs and call SSNVs. Applying this process to two
individual patients showed that sequencing of multiple independent CTC libraries can
achieve full coverage of the exome territory accessible in bulk sequencing and a false
positive rate below the expected mutational rate in prostate cancer.
As implemented, the current process works well for patients from whom five or more single
CTCs are recovered from 3.75mL of blood and high-quality libraries generated for
sequencing. The numbers of CTCs can vary substantially among different types of cancer12,
so sequencing of CTCs may not directly apply to all cancer patients. Nonetheless, advancing
the individual technologies used to recover and amplify as many CTCs as possible from
patients would increase the numbers of cancers for which this approach could benefit. For
instance, enriching CTCs based on physical separation or microfluidics rather than
expression of EpCAM6, processing greater volumes of blood or using other means of WGA
that improve uniformity in genome-wide coverage of the amplified DNA could all increase
the numbers of CTC libraries available15. The designed modularity of our approach can
accommodate new emerging operations for the enrichment and isolation of CTCs, WGA30
and sequencing platforms. Furthermore, as the costs of library preparation, hybrid selection
and sequencing decline, we anticipate census-based sequencing will become more cost-
effective for monitoring more patients.
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CTCs. Such analysis of heterogeneity is extremely challenging because variants in
individual cells can either be absent for technical (allelic distortion, false positive) or
biological (subclonality in the population) reasons. Although we identified many mutations
in single libraries, our census-based approach deprioritizes them because we could not
distinguish them from false positives. Exome sequencing of ctDNA has also demonstrated
concordance of variants with tumor biopsies29. Although such DNA is fragmented and has
similarly low abundance, these materials may provide a complementary source for reducing
false positive calls or revealing other mutations not sampled among sparse CTCs.
Nonetheless, our results suggest that CTC sequencing could augment both large-scale efforts
to map the genetics of cancer and clinical sequencing from individual cancer patients where
a focus on evolutionarily early and shared metastatic events such as those identified by the
proof-of-concept case herein are critical for precision medicine. The integrated process may
also enable longitudinal monitoring of the genetic state of disseminated cancer, revealing
important insights in tumor evolution, metastatic dissemination and the resistance to
therapeutics.
ONLINE METHODS
Patient recruitment
Eligible patients were metastatic castration-resistant prostate cancer (CRPC) patients who
had 1) progression on a phase II study of abiraterone in combination with dutasteride (DFCI
Protocol # 10–448, IRB expiration date 2/7/2014) or 2) PSA >20 ng/ml and progressive
disease based on rising PSA and scan progression to enrich for patients likely to have
detectable circulating tumor cells. There is no PSA cutoff for the phase II study itself. The
Prostate Clinical Research Information System (CRIS) database at Dana-Farber Cancer
Institute was used to identify metastatic CRPC patients. The CRIS system comprises data-
entry software, a central data repository, collection of patient data including comprehensive
follow-up of all patients, and tightly integrated security measures, as previously described33.
All patients provided written informed consent to allow the collection of tissue and blood
and the analysis of clinical and genetic data for research purposes (DFCI Protocol # 01–045,
IRB expiration date 3/20/2014). After initial screening of patients with metastatic CRPC,
chart review was performed by a physician to identify those who had progressive disease
described above. Blood specimens were prospectively collected from eligible patients. Refer
to Supplementary Table 1 for patient information. Blood was drawn in EDTA tubes and
transported at room temperature to the Broad Institute within 3 hours.
Patient characteristics
The clinical course of the patient described here was as follows: At the age of 54, the patient
was diagnosed with a T3, Gleason 9, PSA 10 prostate cancer. He was treated on a research
trial of neoadjuvant docetaxel and bevacizumab. At prostatectomy he had a pT3b, N1 tumor.
He next received adjuvant radiation and androgen deprivation therapy (ADT). Upon rising
PSA continuous ADT was reinitiated and he was treated with sequential bicalutamide and
nilutamide. Seventeen months after initial diagnosis he developed metastases and was
treated with the following therapies until his death 6 years after his presentation: docetaxel,
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tphase 1 trial of PI3-kinase/MEK kinase inhibitor, sipuleucel-T, XL-184, abiraterone,
enzalutamide, cabazetaxel, palliative radiation to bone and combined abiraterone/
enzalutamide. At the time of CTC isolation, he received abiraterone/enzalutamide, and a
lymph node biopsy was performed while he received enzalutamide. A basic summary of the
timeline of events is illustrated in Fig. 3d.
Enrichment of CTCs from blood
For each 3.75 mL of blood, red blood cell (RBC) lysis was first performed using 1× Pharm
Lyse solution (BD Biosciences). The RBC-depleted sample was then incubated with 4 tests
of FITC-anti-CD45 (eBiosciences; clone HI30) for 30 min at 4 °C, followed by incubation
with anti- EpCAM magnetic beads (Illumina)16 for 30 min at 4 °C. PE-anti-EpCAM (BD
Biosciences; clone EBA-1) was then added for 30 min at 4 °C prior to immunomagnetic
isolation using the Illumina MagSweeper16.
Isolation of CTCs
Isolation of CTCs from the enriched samples from the MagSweeper was performed using
either the nanowell-based method with automated imaging and robotic retrieval of single
cells, or a 6-well dish with manual imaging and pipetting. For the nanowell-based approach,
enriched samples were loaded into the wells of a 1 × 3 inch polydimethylsiloxane nanowell
device containing a 24 × 72 array of 7 × 7 wells, each of the dimensions 50 × 50 × 50 µm
(Supplementary Fig. 2)34. Automated epifluorescence imaging of the array was performed
(Zeiss) and images were processed using a custom software program. Following manual
review of candidate cells via a custom CTC analysis software (EVA), candidate CTCs
(DAPI− CD45− EpCAM+) were retrieved from individual wells of the device using an
automated robotic micromanipulator (CellCelector, ALS) and deposited within 3 µL droplets
of Superblock/PBS (Thermo Scientific) into empty wells of a 96 well PCR plate. For the
manual approach, candidate CTCs (DAPI− CD45− EpCAM+) were recovered from
Superblock/PBS by pipetting 3 µL into a 96 well PCR plate. PCR plates was frozen down at
−80 °C until ready for further processing.
Lysis and whole genome amplification (WGA) of CTCs
Each PCR plate containing frozen CTCs was thawed on ice and the volume of individual
wells was diluted to 5 µL using UltraPure water (Invitrogen). 5 µL of lysis buffer, containing
0.4 M KOH (Sigma Aldrich) and 80 mM DTT (Qiagen), was added to each well and the
plate was sealed, gently shaken to mix, spun down at 300 rcf for 1 min, and incubated for 10
min at 50 °C using a thermal cycler (Eppendorf). Following lysis, the plate was spun down
at 300 rcf for 1 min, and 5 µL of 0.4 M HCl (Fluka), was added to each well, and the plate
was kept on ice. Master mix for whole genome amplification by multiple displacement
amplification (MDA) was prepared by adding, for each reaction, 26.25 µL of sterile water, 5
µL of 10× reaction buffer from the RepliPHI kit (Epicentre), 0.5 µL of 10 mg/mL BSA
(NEB), 0.2 µL of 1 M DTT (Qiagen), 0.8 µL of 25 mM dNTPs from the RepliPHI kit
(Epicentre), 1.25 µL of 10 mM random hexamers (NNNN*N*N) from IDT, and 1 µL of
RepliPHI enzyme from the RepliPHI kit (EpiCentre). 35 µL of this master mix was added to
each well of the PCR plate, containing lysed genomic DNA, and incubated for 2 h at 30 °C
on a thermal cycler (Eppendorf). Following the MDA reaction, clean up was performed
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to each sample and incubated for 5 min at room temperature. The samples were then placed
on a 96-well plate magnet (Invitrogen) and incubated for 5 min. Supernatant was removed
from each sample and 100 µL of fresh 70% ethanol (Koptec) was added and removed twice
to wash the beads. Following complete removal of the ethanol and drying for 10 min at
room temperature, beads were resuspended in 60 µL of Tris-EDTA buffer, pH 8 (Teknova),
incubated for 5 min at room temperature, placed back on the magnet for 5 min, then
cleaned-up products were removed to a new PCR plate. These MDA products were
quantified using the Quant-IT PicoGreen dsDNA assay kit (Invitrogen), and products with
concentrations greater than the negative control were selected for low-pass whole-genome
sequencing (WGS).
Library preparation and low-pass whole genome sequencing
Whole genome sequencing libraries were prepared using the Nextera DNA Sample Prep Kit
(Illumina), quantified using the Library Quantification Kit for Illumina (Kapa Biosystems),
and pooled and loaded at 12 pM onto the Illumina MiSeq sequencer using the MiSeq
Reagent Kit v2 (Illumina). Up to 96 libraries can be multiplexed in the same run. The MiSeq
Reporter (Illumina) was used to align reads and generate BAM files, and IGV Tools (Broad
Institute) was used to bin the genome for coverage at 1 Mb intervals and generate TDF files.
The TDF files were viewed in the Integrative Genomics Viewer (IGV) to visually inspect
genome-wide uniformity in coverage of each MDA product.
Calculation of autocorrelation coefficient and selection of CTC libraries
Using the data from low-pass whole genome sequencing, we computed the degree of
correlation in single-base coverage over various distances, normalized by the mean target
coverage, for each library. The Depth Of Coverage module from GATK was used to
compute single-base coverage (http://www.broadinstitute.org/gatk/) using a minimum
mapping quality of 5, and the autocorrelation coefficient represents the magnitude (not the
length-scale or genomics distance of correlation) of the correlation in single base coverage at
1 kb distances normalized by the mean sequencing depth. 1 kb represents a length scale well
above the average fragment length, yet short enough to capture local biases in coverage due
to preferential overamplification in WGA. In our study, the autocorrelation analysis was
computed over chromosome 1 because it is the largest chromosome, does not have visible
copy-number alterations from both WGS and WES read coverage, and provides the analysis
the most statistical power. The analysis could have been performed on other chromosomes
too. Chromothripsis, although rare, would only affect the correlation near translocation
junctions, which would be a small fraction of the chromosome and would have negligible
effects on the analysis.
Libraries were ranked based on autocorrelation coefficient. In this study, we selected
libraries for whole exome sequencing that had the logarithm of (1 / autocorrelation
coefficient) greater than −1.8. In the rare event of insufficient coverage (~0.0001×) for
computing of the autocorrelation coefficient, visual inspection of genome-wide read
densities may be used to include samples with seemingly uniform genomic coverage, as
demonstrated in Supplementary Fig. 6.
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Genomic DNA was isolated from blood to control for germline variants using the DNeasy
Blood and Tissue Kit (Qiagen). 100 µL of anticoagulated blood was added to 20 µL
proteinase K and adjusted to 220 µL volume with PBS. 200 µL of Buffer AL was added,
mixed, and incubated at 56 °C for 10 minutes. All subsequent steps were performed per the
manufacturer’s recommendations.
Genomic DNA and RNA were isolated from primary tumor tissue using the AllPrep
DNA/RNA Mini Kit (Qiagen), and from metastatic tumor tissue using AllPrep DNA/RNA
Micro Kit (Qiagen) following the manufacturer’s recommendations. Primary tumor tissue
consisted of blocks of fresh frozen tissue acquired at the time of radical prostatectomy,
frozen in OCT medium, and stored in liquid nitrogen at the Gelb Center for Translational
Research. Accompanying slides were reviewed by a pathologist and tumor boundaries were
marked at the time of storage. Slides were re-reviewed at the time of retrieval for presence
of tumor, and regions of Gleason 3, 4, and 5 within the tumor were identified and areas were
marked. Nine representative tumor foci were chosen to maximize distance between the
cores, favoring higher Gleason grade regions. Each block was removed from the cassette,
placed on a petri dish on dry ice to keep cold, and aligned with the accompanying marked
slide to identify the selected foci. Blocks were cored using a Miltex 2mm Disposable Biopsy
Punch with Plunger, placed into a DNA LoBind Eppendorf tube, and stored at −80 °C until
time of nucleic acid extraction.
Metastatic tumor tissue consisted of blocks of fresh frozen tissue acquired from excision of
left supraclavicular lymph node and frozen in OCT medium. Tumor shavings were obtained
at the time of sectioning the OCT block for immunohistochemistry. About 100–300 micron
shavings were obtained using a cryostat, placed into a DNA LoBind Eppendorf tube, and
stored at −80 °C until time of nucleic acid extraction.
Selection of libraries and whole exome sequencing
Whole exome sequencing was performed as previously described35. Briefly, 100 ng of DNA
from each sample was used for library preparation, which included shearing and ligation of
sequencing adaptors. Exome capture was performed using the Agilent v2 Human Exon bait
kit. Captured DNA was sequenced using the Illumina HiSeq platform, and paired-end
sequencing reads were generated for each sample. Initial alignment and quality control were
performed using the Picard and Firehose pipelines at the Broad Institute. Picard generates a
single BAM file for each sample that includes reads, calibrated quantities, and alignments to
the genome. Firehose represents a set of tools for analyzing sequencing data from tumor and
matched normal DNA. The pipeline uses GenePattern as its execution engine, and performs
quality control, local realignment, mutation calling, and coverage calculations, among other
analyses. Complete details of this pipeline can be found in Stransky et al 201136 or at the
following website: www.broadinstitute.org/cancer/cga/. Sequencing was performed to an
average target coverage of > 120×.
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Reads were aligned to the reference human genome build hg19 through implementation of
the Burrows-Wheeler Aligner37 and processed through Picard38. The Firehose pipeline
(www.broadinstitute.org/cancer/cga) was used to manage input and output files and submit
analyses for execution. MuTect was used to identify somatic single-nucleotide variants
(SSNVs) in targeted exons by Bayesian statistical analysis of bases and their qualities in the
tumor and normal BAMs at each given genomic locus; the MuTect publication describes the
specificity and sensitivity of the method18. Reads from all SSNV candidates were then
realigned more stringently by disregarding read pair information to reduce alignment based
artifacts. All SSNVs were subjected to filtering against a large panel of normal samples, in
order to remove common artifacts that escaped the original calling algorithms39. Further,
only sites within chromosomes one through 22 and X were considered. Sites in the exomes
of primary samples and metastasis were considered to be powered for mutation calling if the
number of reads at a site allowed for a 0.9 probability of observing 3 supporting reads of the
alternate allele, considering purity of the sample and assuming a minimum cancer cell
fraction of 0.1. Sites were considered powered in CTCs if 5 CTCs had coverage of > 3 reads
(this achieves ~98% power to detect a clonal mutation, based on a maximum loss of
coverage of 14.4% of the alternate allele only across the CTCs as determined in Fig. 2a).
Calculation of False Positive Rate
To calculate the effective false positive rate of the method, we computed the total number of
potential false positive events, and the territory at risk for these events. To calculate an upper
bound for the number of events, we assumed every event was a false positive after removing
events seen independently in at least one of the primary tumor cores or metastasis. To
calculate the denominator of the false positive rate, the number of bases that were at risk for
a mistake being made, we considered the effects of bi-allelic dropout as this leads to regions
of the genome with no coverage, and thus no possibility of false positive occurring. Bi-
allelic drop out was calculated from germline heterozygous single-nucleotide
polymorphisms (SNPs) (see Fig. 2b). We then used a binomial model to calculate the
probability of having k or more observations in n CTCs using 1 minus the median value of
the estimated fraction of sites without bi-allelic dropout (0.33) as the probability of each
CTC having coverage and multiplied by the approximate size of the original targeted exome
territory (~32 Mb) to arrive at the total number of bases at risk.
RNA sequencing of single CTCs
Single CTCs were recovered, using the nanowell-based isolation platform, into individual
wells of a 96 well plate containing 10 µL of buffer TCL (Qiagen) supplemented with 1% 2-
mercaptoethanol (Sigma), spun down, snap frozen on dry ice, and stored at −80 °C until
further processing. Next, RNA from each single CTC was isolated, reverse transcribed, and
amplified using the SMARTer Ultra-low RNA kit (Clontech) as previously described32.
Afterwards, cDNA libraries were prepared using Nextera XT DNA Sample preparation
reagents (Illumina) as per the manufacturer’s recommendations, with minor modifications.
Specifically, reactions were run at ¼ the recommended volume, the tagmentation step was
extended to 10 minutes, and the extension time during the PCR step was increased from 30s
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tto 60s. After the PCR step, all 96 samples were pooled without library normalization,
cleaned twice with 0.9× AMPure XP SPRI beads (Beckman Coulter), and eluted in Tris-
EDTA buffer, pH 8 (Teknova). The pooled libraries were quantified using Quant-IT DNA
High-Sensitivity Assay Kit (Invitrogen) and examined using a high sensitivity DNA chip
(Agilent). Finally, samples were sequenced using a MiSeq sequencer (Illumina).
Analysis of RNA sequencing data
Raw sequencing data were processed as described previously32, except that there was no
need to trim SMARTer short and long adapter sequences due to the Nextera library
preparation40. Short sequencing reads were aligned to the UCSC hg19 transcriptome. These
alignments were used to estimate transcriptomic alignment rates, and were also used as input
in RSEM v 1.1241 to quantify gene expression levels (transcripts per million; TPM) for all
UCSC hg19 genes in all samples. Genomic mappings were performed with Tophat v.
1.4142, and the resulting alignments were used to calculate genomic mapping rates, rRNA
contamination, and 3’ and 5’ positional bias38.
Cell spike-in experiments
LNCaP prostate cancer cells (ATCC) were cultured in RPMI-1640 medium (Corning,
Cellgro) supplemented with 10% fetal bovine serum (FBS, Sigma). To determine surface
expression of EpCAM, LNCaP cells were stained with anti PE-anti-EpCAM (BD
Biosciences; clone EBA-1) and the level of expression was determined by flow cytometry
on a LSRII (BD Biosciences), compared to unstained control. For technical validation of the
MagSweeper enrichment procedure, LNCaP cells were labeled with carboxyfluorescein
diacetate succinimidyl ester (CFDA, Invitrogen) and spiked into normal blood (obtained
from Research Blood Components, LLC) at the indicated concentrations prior to
MagSweeper enrichment. Successful isolation of LNCaP cells was determined by
determining the number of CFDA-labeled cells by microscopy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Experimental process for sequencing of CTCs. (a) Schematic of workflow for the
enrichment, isolation and sequencing of CTCs. (b) Sample micrographs of CTCs isolated in
nanowells are shown with matched transmitted light (T.L.) and immunophenotyping for
EpCAM, CD45, and DAPI by epifluorescence. Scale bar denotes 50 µm. (c) Scatter plot of
the number of CTCs enumerated versus levels of PSA from 51 blood samples from 36
prostate cancer patients (Supplementary Table 1) screened using the MagSweeper for
enrichment. CTC numbers in blood correlated with PSA levels (p = 0.004; Spearman, two-
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ttailed). (d) Scatter plot of the percentage of target bases covered > 20× from whole exome
sequencing (WES) versus the autocorrelation coefficient (Online Methods) calculated from
low pass whole genome sequencing (WGS) over chromosome 1 for patient CRPC_36 (p <
0.0001; Pearson, two-tailed). WES yielded 124 ± 12× mean target coverage (Supplementary
Table 2). WGS yielded mean coverage over chromosome 1 between 0.0003× and 0.03×,
with a median of 0.017×. (e) Genome-wide read densities (1 Mb bins) from low pass WGS
of CTC libraries from four different patients (CRPC_10, CRPC_12, CRPC_35, CRPC_36).
Examples of three quality libraries and one poor library are shown per patient. The log of the
inverse correlation coefficient was used to select high-quality libraries, with a cut off of −1.8
used here.
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Census-based variant calling from whole exome sequencing of CTCs from patient
CRPC_36. (a) Characterization of allelic coverage in each CTC sequencing library from the
same patient, compared to those libraries combined and primary tumor, as determined by
22,054 germline heterozygous SNP sites; an allele was scored as covered if there were ≥ 3
total reads of the particular allele(s). For reference, the autocorrelation coefficient is plotted
below all CTC libraries except for three CTC libraries (n.d., not determined) that had
insufficient low pass WGS coverage but passed quality control prior to exome sequencing
based on visual inspection of genome-wide read densities (Supplementary Fig. 6). Coverage
of the alternate allele (either alternate alone or both alleles) at germline heterozygous SNPs
was correlated with the autocorrelation metric for individual CTC libraries (p < 0.0001;
Spearman, two-tailed). When the individual CTC libraries were combined (“combined
CTCs”), 99.995% of sites were covered by both alleles, similar to bulk sequencing of the
primary tumor. (b) Estimation of false positive rate / Mb among 19 independent CTC
libraries after requiring the variant to be observed in at least N independent CTC libraries
(Supplementary Fig. 10). Grey dashed line indicates the reported mutation rate in bulk tumor
sequencing of treated prostate cancer (~2 / Mb)19; black arrow head indicates the false
positive rate / Mb observed for a single CTC library. Inset shows sensitivity versus false
positive rate / Mb as a function of the required number N of independent observations of the
variant. (c) The number of SSNVs called in total among 19 CTC libraries (73) and those that
were validated as being present in matched tumor tissue (51) are shown. (d) Relative
sensitivity to call CTC SSNVs (fraction of the total number called using 19 CTC libraries)
as a function of the number of libraries sequenced, ranked in order by the autocorrelation
coefficient (blue bars). A sustained improvement in sensitivity was observed. Additionally,
considering only the 51 CTC SSNVs also observed in bulk whole exome sequencing of
matched tumor tissue, we observed a very similar increase in sensitivity for each additional
library sequenced (grey bars).
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Comparison of mutation pattern across CTCs, primary cores and metastasized tumor from
patient CRPC_36. (a) FDG-PET and bone scans show widespread metastatic disease. FDG-
PET Maximum Intensity Projection (MIP) image (top left) and axial FDG-PET slice
(bottom left) demonstrate multifocal FDG-avid skeletal metastases throughout the axial and
appendicular skeleton as well as bilateral cervical, left supraclavicular (arrow),
retroperitoneal and bilateral common iliac metastatic lymphadenopathy. Bone scan
demonstrates widespread bone metastasis. (b) Venn diagram representing mutations called
in the CTCs and metastasis. Of note, 51% of mutations in the metastasis were called in
CTCs. (c) Hierarchical clustering using the Jaccard index for mutations called across the
nine primary cores, metastasized tumor and CTCs (when observed in ≥3 out of 19 single
CTCs). Only sites in the exomes that were considered to be powered for mutation calling, as
described in Online Methods, were included in this analysis. Shading of green represents
presence in CTCs and at least one other sample (dark green) or not present in CTCs (light
green). Genes highlighted indicate non-synonymous mutations present in >2 patients from a
previous sequencing study in prostate cancer31. Of note, one of the cores included regions of
both Gleason 3 and Gleason 5 cancer. (d) Dendrogram representing hierarchical clustering
by the Jaccard index, and timeline of sample acquisition. SSNVs detected in all individual
cores of tissue (early trunk), or in all cores that belong to only one of the two branchpoints
of the clustering dendrogram are listed. Non-synonymous mutations are highlighted in bold
with “*”. The areas shaded in pink represent the pathology blocks from which cores of
tissue were obtained (drawn to scale). The dotted lines represent the area with histological
presence of tumor within each block. The sites from which the individual cores of tissue
were obtained for sequencing are displayed in colors corresponding to the cluster
dendrogram and Fig. 3c. The regions of the prostate from which the pathology blocks were
retrieved are schematized. (e) The number of mutations found in the metastasis and at least
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tone core of the primary tumor (metastatic trunk), the early trunk mutations, and the overlap
of these with CTC mutations are shown, excluding sites that were consistently
underpowered in greater than half of the samples. The one early trunk mutation not detected
in CTCs (N ≥ 3) was observed in 2 CTCs.
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